LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 224

Search options

  1. Article: Editorial: The Evolving Role of Immunotherapy in Non-Melanoma Skin Cancers.

    Guida, Michele / Quaglino, Pietro / Queirolo, Paola

    Frontiers in oncology

    2022  Volume 12, Page(s) 870509

    Language English
    Publishing date 2022-05-18
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2022.870509
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: New insights in melanoma biology: Running fast towards precision medicine.

    Limonta, Patrizia / Queirolo, Paola

    Seminars in cancer biology

    2019  Volume 59, Page(s) 161–164

    MeSH term(s) Disease Susceptibility ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Melanoma/drug therapy ; Melanoma/etiology ; Melanoma/metabolism ; Melanoma/pathology ; Molecular Targeted Therapy ; Precision Medicine ; Signal Transduction/drug effects
    Language English
    Publishing date 2019-09-25
    Publishing country England
    Document type Editorial ; Introductory Journal Article
    ZDB-ID 1033980-2
    ISSN 1096-3650 ; 1044-579X
    ISSN (online) 1096-3650
    ISSN 1044-579X
    DOI 10.1016/j.semcancer.2019.09.019
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2922: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: The Role of Nicotinamide as Chemo-Preventive Agent in NMSCs: A Systematic Review and Meta-Analysis.

    Tosti, Giulio / Pepe, Francesca / Gnagnarella, Patrizia / Silvestri, Flavia / Gaeta, Aurora / Queirolo, Paola / Gandini, Sara

    Nutrients

    2023  Volume 16, Issue 1

    Abstract: Background: Nicotinamide is the active form of vitamin B3 (niacin) obtained through endogenous synthesis, mainly through tryptophan metabolism and dietary supplements, fish, meats, grains, and dairy products. It participates in cellular energy ... ...

    Abstract Background: Nicotinamide is the active form of vitamin B3 (niacin) obtained through endogenous synthesis, mainly through tryptophan metabolism and dietary supplements, fish, meats, grains, and dairy products. It participates in cellular energy metabolism and modulates multiple cellular survival and death pathways. Nicotinamide has been widely studied as a safe chemopreventive agent that reduces actinic keratosis (AKs) and non-melanoma skin cancers (NMSC).
    Methods: We used the Medline, EMBASE, PubMed, and Cochrane databases to search the concepts "nicotinamide", "chemoprevention", and "skin cancer" up to August 2023. Three independent authors screened titles and abstracts for intervention and study design before searching full texts for eligibility criteria. The primary outcome was the impact of oral nicotinamide on the incidence of NMSC in high-risk patients. We also conducted a systematic search to identify relevant epidemiological studies published evaluating dietary niacin intake and the risk of NMSC.
    Results: Two hundred and twenty-five studies were reviewed, and four met the inclusion criteria. There was no association between NAM consumption and risk for squamous cell carcinoma (SCC) (rate ratio (RR) 0.81, 95% CI 0.48-1.37; I
    Conclusions: The present meta-analysis shows, by pooling immunocompetent and immunosuppressed patients, that there is insufficient evidence that oral nicotinamide therapy significantly reduces the number of keratinocyte cancers.
    MeSH term(s) Animals ; Humans ; Niacinamide ; Niacin ; Chemoprevention ; Skin Neoplasms/epidemiology ; Skin Neoplasms/prevention & control ; Carcinoma, Basal Cell ; Carcinoma, Squamous Cell
    Chemical Substances Niacinamide (25X51I8RD4) ; Niacin (2679MF687A)
    Language English
    Publishing date 2023-12-27
    Publishing country Switzerland
    Document type Meta-Analysis ; Systematic Review ; Journal Article ; Review
    ZDB-ID 2518386-2
    ISSN 2072-6643 ; 2072-6643
    ISSN (online) 2072-6643
    ISSN 2072-6643
    DOI 10.3390/nu16010100
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Metastatic melanoma: how research can modify the course of a disease.

    Queirolo, Paola / Pfeffer, Ulrich

    Cancer metastasis reviews

    2017  Volume 36, Issue 1, Page(s) 3–5

    MeSH term(s) Antibodies, Monoclonal/immunology ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents/therapeutic use ; Humans ; Immunotherapy ; Melanoma/immunology ; Melanoma/pathology ; Melanoma/urine ; Neoplasm Metastasis ; Programmed Cell Death 1 Receptor/immunology ; Programmed Cell Death 1 Receptor/therapeutic use
    Chemical Substances Antibodies, Monoclonal ; Antineoplastic Agents ; Programmed Cell Death 1 Receptor
    Language English
    Publishing date 2017-02-14
    Publishing country Netherlands
    Document type Introductory Journal Article
    ZDB-ID 604857-2
    ISSN 1573-7233 ; 0167-7659
    ISSN (online) 1573-7233
    ISSN 0167-7659
    DOI 10.1007/s10555-017-9664-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1812: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma.

    Queirolo, Paola / Spagnolo, Francesco

    Cancer metastasis reviews

    2017  Volume 36, Issue 1, Page(s) 35–42

    Abstract: BRAF plus MEK-targeted drugs have out-performed BRAF inhibitor monotherapy in three randomized phase 3 studies, and such combinations have become a new standard of treatment for BRAF-mutant advanced melanoma. With an overall response rate of about 70%, ... ...

    Abstract BRAF plus MEK-targeted drugs have out-performed BRAF inhibitor monotherapy in three randomized phase 3 studies, and such combinations have become a new standard of treatment for BRAF-mutant advanced melanoma. With an overall response rate of about 70%, no other therapy in melanoma has shown a better response rate in late-phase clinical trials than combined BRAF and MEK inhibitors; the rapid kinetics of response make them the ideal front-line treatment for symptomatic, BRAF-mutant advanced melanoma patients. Nevertheless, the development of mechanisms of resistance limits the duration of response to such treatment in the majority of cases, with only about 20% of patients treated with the combination being progression-free at 3 years. The aim of this review is to report the efficacy and safety outcomes of the combination of BRAF plus MEK inhibitors compared with BRAF inhibitor monotherapy and immunotherapy, as well as to discuss future perspectives to improve outcomes based on current clinical and translational research studies.
    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Humans ; MAP Kinase Kinase Kinases/antagonists & inhibitors ; Melanoma/drug therapy ; Melanoma/enzymology ; Melanoma/genetics ; Molecular Targeted Therapy ; Mutation ; Proto-Oncogene Proteins B-raf/antagonists & inhibitors ; Proto-Oncogene Proteins B-raf/genetics
    Chemical Substances BRAF protein, human (EC 2.7.11.1) ; Proto-Oncogene Proteins B-raf (EC 2.7.11.1) ; MAP Kinase Kinase Kinases (EC 2.7.11.25)
    Language English
    Publishing date 2017
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 604857-2
    ISSN 1573-7233 ; 0167-7659
    ISSN (online) 1573-7233
    ISSN 0167-7659
    DOI 10.1007/s10555-017-9660-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1812: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Binimetinib for the treatment of NRAS-mutant melanoma.

    Queirolo, Paola / Spagnolo, Francesco

    Expert review of anticancer therapy

    2017  Volume 17, Issue 11, Page(s) 985–990

    Abstract: Introduction: Activating NRAS mutations occur in approximately 15-20% of melanomas and are the second most common oncogenic driver mutation in this disease, after BRAF mutations. There is an unmet medical need for new targeted therapy opportunities in ... ...

    Abstract Introduction: Activating NRAS mutations occur in approximately 15-20% of melanomas and are the second most common oncogenic driver mutation in this disease, after BRAF mutations. There is an unmet medical need for new targeted therapy opportunities in metastatic patients whose tumors harbor an NRAS mutation. Binimetinib, a mitogen-activated protein kinase kinase (MEK) inhibitor, has shown clinical activity in this group of patients. Areas covered: The purpose of this paper was to review the safety, activity and efficacy of the MEK inhibitor binimetinib for the treatment of NRAS-mutant melanoma, as well as to discuss future therapeutic perspectives such as multiple pathways, targeted therapy, and combinations with immunotherapy. Expert commentary: Only a modest progression-free survival (PFS) benefit was observed in NRAS-mutated patients who received binimetinib compared with dacarbazine in a randomized phase 3 clinical trial, with no improvement in overall survival. Nevertheless, binimetinib represents another promising treatment option for advanced melanoma and the first molecularly targeted therapy for the NRAS-mutant population. Binimetinib may also have a role in treating NRAS-mutated melanoma patients after failure of immunotherapy.
    MeSH term(s) Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Benzimidazoles/adverse effects ; Benzimidazoles/pharmacology ; Benzimidazoles/therapeutic use ; Disease-Free Survival ; GTP Phosphohydrolases/genetics ; Humans ; Immunotherapy/methods ; Melanoma/drug therapy ; Melanoma/genetics ; Melanoma/pathology ; Membrane Proteins/genetics ; Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors ; Molecular Targeted Therapy ; Mutation ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Randomized Controlled Trials as Topic ; Survival Rate
    Chemical Substances Antineoplastic Agents ; Benzimidazoles ; MEK162 ; Membrane Proteins ; Protein Kinase Inhibitors ; Mitogen-Activated Protein Kinase Kinases (EC 2.7.12.2) ; GTP Phosphohydrolases (EC 3.6.1.-) ; NRAS protein, human (EC 3.6.1.-)
    Language English
    Publishing date 2017-11
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2112544-2
    ISSN 1744-8328 ; 1473-7140
    ISSN (online) 1744-8328
    ISSN 1473-7140
    DOI 10.1080/14737140.2017.1374177
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5907: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review.

    Queirolo, Paola / Spagnolo, Francesco

    Cancer treatment reviews

    2017  Volume 59, Page(s) 71–78

    Abstract: Anti-programmed death receptor 1 (PD-1) drugs nivolumab and pembrolizumab were recently approved for the treatment of advanced melanoma and other solid tumors. Atypical patterns of response (i.e. tumor shrinkage or stabilization after initial progression) ...

    Abstract Anti-programmed death receptor 1 (PD-1) drugs nivolumab and pembrolizumab were recently approved for the treatment of advanced melanoma and other solid tumors. Atypical patterns of response (i.e. tumor shrinkage or stabilization after initial progression) were observed in about 10% of metastatic melanoma patients treated with anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) drug ipilimumab and were associated with improved survival; however, the rate of atypical response patterns to anti-PD-1 therapy is not clear. An electronic search was performed to identify clinical trials evaluating response to anti-PD-1 therapy with nivolumab and pembrolizumab in patients with advanced solid tumors. Thirty-eight studies were included in our analysis for a total of 7069 patients with advanced cancer treated with anti-PD-1 therapy. Responses were evaluated by unconventional response criteria in 19 trials and were observed for all cancer types but tumors with mismatch-repair deficiency and head and neck squamous cell carcinoma. Overall, 151 atypical responses were observed in 2400 patients (6%) evaluated by unconventional response criteria. The results of our systematic review highlight the clinical relevance of unconventional responses to anti-PD-1 therapy and support further investigation into the development of tools that may assist evaluation of the antitumor activity of immunotherapy.
    MeSH term(s) Adult ; Aged ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Carcinoma, Renal Cell/drug therapy ; Carcinoma, Renal Cell/mortality ; Carcinoma, Renal Cell/pathology ; Clinical Trials, Phase I as Topic ; Clinical Trials, Phase II as Topic ; Clinical Trials, Phase III as Topic ; Disease-Free Survival ; Female ; Humans ; Kidney Neoplasms/drug therapy ; Kidney Neoplasms/mortality ; Kidney Neoplasms/pathology ; Lung Neoplasms/drug therapy ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Male ; Melanoma/drug therapy ; Melanoma/mortality ; Melanoma/pathology ; Middle Aged ; Neoplasms/drug therapy ; Neoplasms/mortality ; Neoplasms/pathology ; Prognosis ; Programmed Cell Death 1 Receptor/drug effects ; Programmed Cell Death 1 Receptor/genetics ; Randomized Controlled Trials as Topic ; Risk Assessment ; Survival Analysis
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; PDCD1 protein, human ; Programmed Cell Death 1 Receptor ; nivolumab (31YO63LBSN) ; pembrolizumab (DPT0O3T46P)
    Language English
    Publishing date 2017-09
    Publishing country Netherlands
    Document type Comparative Study ; Journal Article ; Review
    ZDB-ID 125102-8
    ISSN 1532-1967 ; 0305-7372
    ISSN (online) 1532-1967
    ISSN 0305-7372
    DOI 10.1016/j.ctrv.2017.07.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1022: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 611: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: The adjuvant treatment revolution for high-risk melanoma patients.

    Spagnolo, Francesco / Boutros, Andrea / Tanda, Enrica / Queirolo, Paola

    Seminars in cancer biology

    2019  Volume 59, Page(s) 283–289

    Abstract: The past 5 years have witnessed the results of many practice-changing studies that have dramatically improved the landscape of adjuvant therapy in patients with resected, high-risk melanoma. After a 20-year era of adjuvant interferon, the anti-CTLA-4 and ...

    Abstract The past 5 years have witnessed the results of many practice-changing studies that have dramatically improved the landscape of adjuvant therapy in patients with resected, high-risk melanoma. After a 20-year era of adjuvant interferon, the anti-CTLA-4 and anti-PD-1 immune-checkpoint inhibitors, and MAPK-directed targeted therapy brought a revolution into the adjuvant treatment of melanoma. These results came along with the practice-changing results of two large multicenter studies showing no benefit in terms of overall survival for completion lymph node dissection after positive sentinel node biopsy. In this review, we summarized the current state of the art of the adjuvant treatment of high-risk melanoma, with a view on future perspectives.
    MeSH term(s) Clinical Trials as Topic ; Combined Modality Therapy ; Disease Management ; Humans ; Lymph Node Excision ; Melanoma/mortality ; Melanoma/pathology ; Melanoma/therapy ; Neoadjuvant Therapy/methods ; Neoadjuvant Therapy/trends ; Neoplasm Grading ; Neoplasm Metastasis ; Neoplasm Staging ; Practice Guidelines as Topic ; Treatment Outcome
    Language English
    Publishing date 2019-08-21
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1033980-2
    ISSN 1096-3650 ; 1044-579X
    ISSN (online) 1096-3650
    ISSN 1044-579X
    DOI 10.1016/j.semcancer.2019.08.024
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2922: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Gestione delle reazioni avverse immuno-correlate durante la terapia con inibitori dei checkpoint immunologici.

    Queirolo, Paola / Spagnolo, Francesco

    Recenti progressi in medicina

    2016  Volume 107, Issue 8, Page(s) 407–413

    Abstract: Immunotherapy with anti-CTLA-4 and anti-PD-1 monoclonal antibodies is a breakthrough in the treatment of advanced cancer. The progressively broader indications of such drugs highlights the need of developing algorithms for the management of immune- ... ...

    Title translation Management of immune-related adverse events during treatment with immune checkpoint inhibitors.
    Abstract Immunotherapy with anti-CTLA-4 and anti-PD-1 monoclonal antibodies is a breakthrough in the treatment of advanced cancer. The progressively broader indications of such drugs highlights the need of developing algorithms for the management of immune-related toxicities, as some adverse events may cause sequelae and even death if not managed effectively. Thanks to the collaboration of different specialist from the Gustave Roussy Institute in Paris, guidelines for the management of toxicities during treatment with immune checkpoint inhibitors were recently published on the journal Annals of Oncology. The purpose of this article is to review and discuss such guidelines.
    Language Italian
    Publishing date 2016-08
    Publishing country Italy
    Document type English Abstract ; Journal Article
    ZDB-ID 138266-4
    ISSN 2038-1840 ; 0034-1193
    ISSN (online) 2038-1840
    ISSN 0034-1193
    DOI 10.1701/2332.25060
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 193: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review.

    Spagnolo, Francesco / Boutros, Andrea / Cecchi, Federica / Croce, Elena / Tanda, Enrica Teresa / Queirolo, Paola

    BMC cancer

    2021  Volume 21, Issue 1, Page(s) 425

    Abstract: Background: Treatment beyond progression with immunotherapy may be appropriate in selected patients based on the potential for late responses. The aim of this systematic review was to explore the impact of treatment beyond progression in patients ... ...

    Abstract Background: Treatment beyond progression with immunotherapy may be appropriate in selected patients based on the potential for late responses. The aim of this systematic review was to explore the impact of treatment beyond progression in patients receiving an anti-PD-1/PD-L1 based regimen for an advanced solid tumor.
    Methods: A systematic literature search was performed to identify prospective clinical trials reporting data on overall response rate by immune-related criteria and/or the number of patients treated beyond conventional criteria-defined PD and/or the number of patients achieving a clinical benefit after an initial PD with regimens including an anti-PD-1/PD-L1 agent which received the FDA approval for the treatment of an advanced solid tumor.
    Results: 254 (4.6%) responses after an initial RECIST-defined progressive disease were observed among 5588 patients, based on 35 trials included in our analysis reporting this information. The overall rate of patients receiving treatment beyond progressive disease was 30.2%, based on data on 5334 patients enrolled in 36 trials, and the rate of patients who achieved an unconventional response among those treated beyond progressive disease was 19.7% (based on 25 trials for a total of 853 patients).
    Conclusion: The results of our systematic review support the clinical relevance of unconventional responses to anti-PD-1/PD-L1-based regimens; however, most publications provided only partial information regarding immune-related clinical activity, or did not provide any information at all, highlighting the need of a more comprehensive report of such data in trials investigating immunotherapy for the treatment of patients with advanced tumors.
    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; B7-H1 Antigen/antagonists & inhibitors ; Clinical Trials as Topic ; Disease Progression ; Humans ; Immune Checkpoint Inhibitors/administration & dosage ; Immune Checkpoint Inhibitors/adverse effects ; Immune Checkpoint Inhibitors/therapeutic use ; Neoplasm Metastasis ; Neoplasm Staging ; Neoplasms/drug therapy ; Neoplasms/mortality ; Neoplasms/pathology ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Treatment Outcome
    Chemical Substances B7-H1 Antigen ; CD274 protein, human ; Immune Checkpoint Inhibitors ; Programmed Cell Death 1 Receptor
    Language English
    Publishing date 2021-04-17
    Publishing country England
    Document type Journal Article ; Systematic Review
    ISSN 1471-2407
    ISSN (online) 1471-2407
    DOI 10.1186/s12885-021-08165-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top